T
he majority of benign lesions of the adrenal cortex leading to Cushing syndrome are linked to one or another abnormality of the cAMP/protein kinase A (PKA) signaling pathway (1) (2) (3) . Inactivating mutations of the PRKAR1A gene coding for the regulatory 1␣-subunit of PKA are responsible for Carney complex (CNC) in the majority of patients (4) . Primary pigmented nodular adrenocortical disease (PPNAD) is the most common endocrine tumor associated with CNC, leading to Cushing syndrome in more than 60% of the patients (4) . Micronodular adrenocortical hyperplasias and some cortisol-producing adenomas are associated with phosphodiesterase (PDE) 11A and phosphodiesterase 8B defects, coded, respectively, by the PDE11A and PDE8B genes (5) (6) (7) (8) .
Somatic GNAS mutations have been described only in a small number of both ACTH-independent macronodular adrenal hyperplasia (AIMAH), also known as massive macronodular adrenocortical disease (MMAD), rarely in cortisol-producing adenomas (3, 9) , and in the context of McCune-Albright syndrome. cAMP/PKA signaling is altered in MMAD as in adrenal tumors with 17q losses or PRKAR1A mutations (1, 10) . Furthermore, common adrenal lesions without germline or somatic GNAS, PRKAR1A, PDE11A, and PDE8B mutations and associated with ACTH-independent Cushing syndrome (CS) had functional abnormalities of the cAMP signaling pathway, such as increased cAMP levels, decreased total PDE, and/or increased PKA activity (2) . Thus, aberrations of cAMP/PKA signaling are essential in the pathogenesis of benign cortisol-producing lesions of the adrenal cortex.
Previous transcriptome studies demonstrated the overexpression of genes that regulate or are part of the Wnt signaling pathway in both PPNAD and MMAD without GNAS mutations (11, 12) . In agreement with these findings, a whole-genome transcriptome profiling of tumors produced by mouse models of Prkar1a haploinsufficiency identified Wnt signaling as the main pathway activated by abnormal cAMP signaling along with cell cycle abnormalities (13) .
In this study, we analyzed the whole-genome expression profile (WGEP) of PPNAD caused by germline PRKAR1A mutations and adrenal lesions harboring somatic GNAS mutations. The data indicated that cAMP activation in adrenal lesions harboring PRKAR1A or GNAS mutations share the downstream activation of some oncogenic signals but differ significantly in their effects on others. These findings are important for the design of molecularly targeted therapies for benign adrenal tumors or hyperplasias leading to CS.
Patients and Methods

Subjects, tissues, DNA studies, and sequencing
Patients were studied under protocols 95CH0059 and 00CH160, both approved by the Institutional Review Board of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). We studied two groups of lesions (Table 1) : group 1 included three microdissected PPNAD samples from patients with CNC caused by three different nonsense PRKAR1A mutations (see text below); and group 2 included three microdissected samples from adrenal lesions that were all caused by the same somatic GNAS mutation (p.R201H): a cortisol-producing adenoma from a patient with AIMAH/ MMAD and CS and two microdissected adenomatous nodules from a patient with MAS and CS (Supplemental Material, published on The Endocrine Society's Journals Online web site at http://jcem.endojournals.org). All tissue samples were carefully dissected out of surrounding periadrenal fat, adrenal capsule, and other structures. In tissues with GNAS mutations, only cortical nodular tissue that was previously sequenced and found to contain the p.R201H mutation was used for the RNA studies. In the case of PPNAD, all samples contained the PRKAR1A mutation in the heterozygote state; special attention was paid to not include RNA from PRKAR1A-haploinsufficient nodules [those that have undergone loss of heterozygosity (LOH) for the 17q22-24 locus of PRKAR1A] because these tissues may have additional genetic and transcriptome changes. Sequencing for the PRKAR1A and GNAS genes was done as has been described elsewhere (9, 10) . The three PRKAR1A mutations were c.177 ϩ 1GϾA, c.101_105delCTATT, and c.491_492delTG, respectively; they all lead to predicted truncated proteins and their mRNA undergo nonsense-mediated decay (NMD) and are not expressed (4).
Microarray analysis
Total RNA extraction was performed from all tissues using the Trizol reagent method (Invitrogen, Carlsbad, CA). Samples were further purified using the RNeasy columns (QIAGEN, Valencia, CA), and the quality of RNA was assessed using the Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA). Three commercially available pools of human adrenal total RNA (CLONTECH, Mountain View, CA; BioChain, Hayward, CA; Ambion, Austin, TX) were used as reference samples. The normal reference RNA that was used was total adrenal-derived RNA. Preparation of cRNA from total RNA, hybridization in Sentrix HumanRef-8 Expression BeadChips (Illumina, San Diego, CA), scanning, and image analysis was done as previously described (14) . Analysis of Illumina data were performed using Illumina BeadStudio software (Illumina), which returns the trimmed mean average intensity for each single gene probe type (nonnormalized). Any gene consistently with a P detection value above 0.01 for all samples was eliminated from further analysis. Z-transformation for normalization was performed for each Illumina sample/array (14) . First, the raw intensity data for each sample were log 10 transformed, and Z scores were calculated by subtracting the overall average gene intensity (within a single experiment) from the raw intensity data for each gene and then dividing that result by the SD of all of the measured intensities. Changes in gene expression (ratio) between different Z-transformed data sets (nodules compared with the average of the normal adrenal pools) were calculated as differences between the corresponding Z scores and then divided by the SD of each Z difference data set (14) . A 2-fold change was used as the cutoff value to identify over-and underexpressed genes in adrenal nodules in relation to normal adrenal pools. Microarray data are in compliance with the Minimal Information About a Microarray Experiment format. The raw and normalized microarray data reported in this paper have been deposited in the Gene Expression Omnibus database (accession no. GSE 33694).
Analysis of mRNA profiling and validation
The WGEP was analyzed using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) Bioinformatic Resources 2008 (National Institute of Allergy and Infectious Diseases, National Institutes of Health, http://david. abcc.ncifcrf.gov/home.jsp) (15, 16) . The lists of genes (induced or repressed) were submitted to the DAVID database genes are clustered according to a series of common key words. The proportion of each key word in the list is compared with the one in the whole genome, making it possible to compute P values and enrichment scores (geometric mean of the inverse log of each P value). The detailed information of gene alterations was systematically reported on Kyoto Encyclopedia of Genes and Genomes (KEEG) pathways.
Quantitative real-time PCR (qRT-PCR) was performed in the ABI Prism 7700 sequence detector using PCR array plates (SABiosciences, Frederick, MD) and TaqMan gene expression assays (Applied Biosystems, Foster City, CA). The assay identifications were: NFKB1, Hs00765730_m 1 ; RAB13, Hs00762784_s 1 ; RAPGEF4 (EPAC2), Hs00899815_m 1 ; BMP4, Hs00370078_m 1 ; and 18S rRNA, 4352930E. The average of three commercially available pools of human adrenal total RNA (CLONTECH, BioChain, and Ambion) was used as control. Relative quantification was performed using the 2 Ϫ⌬⌬CT method (17).
Protein studies
Western blot analysis was performed following standard procedures (13) . The following primary antibodies were used: beta catenin (CTNNB1; 9587; Cell Signaling, Beverly, MA), nuclear factor-B (NFKB; ab16502; Abcam, Cambridge, MA), inhibitory-B (IKBa; ab32518; Abcam), renin-angiotensin system oncogene family 13 (RAB-13; ab55889; Abcam), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; ab9485; Abcam). All immunohistochemistry was performed at Histoserve, Inc. (Germantown, MD) using standard procedures. The following primary antibodies were used: CTNNB1 (9587; Cell Signaling), NFKB (ab16502; Abcam), and IKBa (ab32518; Abcam). The following grading system was used for staining evaluation: negative (absence of expression), weak staining (from 1 to 25% of immunoreactive cells), and strong staining (Ͼ25% of immunoreactive cells). We also measured the PKA enzymatic activity in tissue extracts as previously described (18) .
Statistical analysis
All statistical analyses were performed with the SPSS 16.0 (SPSS Inc., Chicago, IL). Continuous data are expressed as mean Ϯ SD. All the experiments were performed in triplicate. A two-sample t test was used for paired samples. We considered a P Ͻ 0.05 significant for all comparisons.
Results
Transcriptome analysis, validation, and PKA activity
The gene set enrichment analysis of the WGEP revealed that signaling for P53 and MAPK was significantly enriched in both PRKAR1A-and GNAS-mutant lesions. Adrenal masses with GNAS mutations were significantly en-riched with extracellular matrix (ECM) receptor interaction and focal adhesion pathways when compared with PPNAD (fold enrichment 3.5, P Ͻ 0.0001, and 2.2, P Ͻ 0.002, respectively) (Fig. 1A) . The overexpressed genes in GNAS-mutant lesions compared with those with the PRKAR1A mutations included NFKB1 [nuclear factor of -light polypeptide gene enhancer in B cells 1; ratio (log 10 ) 4.2, P ϭ 0.004], ELK1 (member of the ETS oncogene family; ratio 3.0, P ϭ 0.03), LPAR1 (lysophosphatidic acid receptor 1; ratio 12.6, P ϭ 0.04), RAF1 (v-raf-1 murine leukemia viral oncogene homolog 1; ratio 5.3, P ϭ 0.04), TNFRSF1A (tumor necrosis factor receptor superfamily, member 1A; ratio 4.8, P ϭ 0.05). Expression data were then validated by quantitative PCR and/or Western blot. Indeed, NFKB and NFKBIA expression was higher in GNAS-mutant tumors than in PPNAD samples at messenger and protein levels (P Ͻ 0.05) (Fig. 1, B-D) . EPAC-2 and RAB13, which are activated by a cAMP-dependent but PKA-independent mechanism, were highly expressed in adrenal tumors with GNAS mutations at the mRNA and protein levels (Fig. 1, B and C) but not in those with PRKAR1A mutations. We also analyzed the overlap between the PRKAR1A-and GNAS-mutant lesions. FATE1, FOSB, CXCR4, NOV, PDE2A, NR4A1, NR5A1, NR0B1, FGF9, and CASP9 were among the genes overexpressed in both groups (Supplemental Table 1 ). On the other hand, TH, CART, CHCB, RBP7, RGS4, IGFBP4, and IGFBP3 were among the genes underexpressed in both PRKAR1A-and GNAS-mutant lesions (Supplemental Table 2 ).
This variability in gene expression was not accompanied by significant differences in PKA activity: the latter was measured in five samples ( Fig. 2A) . After cAMP exposure, PKA activity was similar in PPNAD and GNASmutant tumors (35.046 Ϯ 4.753 vs. 39.062 Ϯ 2.757 cpm/mg protein).
Cancer pathways
A qRT-PCR array carrying 84 genes of the Wnt signaling pathway was tested in both GNAS-and PRKAR1A-mutant samples. CCND1, CTNNB1, LEF1, LRP5, WISP1, and WNT3 were overexpressed in PRKAR1A-mutant lesions (Fig. 2B) . Immunohistochemistry for ␤-catenin per se was strongly positive (nuclear and cytoplasmic) in both the PPNAD and GNAS-mutant lesions (Fig. 2, C and D) , but only in nodules in the former.
Apoptosis, cancer, and cell cycle pathways were also studied and compared with normal adrenal pools. Among 84 genes included in the apoptosis array plate, IGF1R, CASP3, CARD6, BAG1, and ABL1 were significantly overexpressed in PRKAR1A-mutant samples (Supplemental Table 3 ). In addition, expression of the oncogenes FGFR2 and RAF1 was significantly higher in PPNAD (Supplemental Table 4 ). Cell cycle genes were also found to be overexpressed in PPNAD (Supplemental Table 5 ), including CDK6, CDK8, CCNC, and CCNT1.
Discussion
In this study, we characterized the expression signature of PPNAD caused by PRKAR1A-truncating mutations and adrenal masses harboring somatic GNAS mutations. In other words, we studied two adrenal lesions that are both caused by genetic defects, leading to increased cAMP/PKA signaling. The MAPK and p53 signaling pathways were enriched in both the PRKAR1A-and GNAS-mutant lesions, but a significant enrichment with the ECM receptor interaction and focal adhesion pathways characterized only the latter. Indeed, proteins involved with ECM receptor interaction and adhesion, such as integrins and their ligands, are induced by EPAC2 (exchange protein directly activated by cAMP; cAMP-GEFII; RapGEF4) activation through a cAMP-dependent but PKA-independent mechanism (19) . Our transcriptome analysis revealed that EPAC2 is overexpressed in MMAD with a GNAS mutation.
NFKB was overexpressed in GNAS-mutant lesions. Lee et al. (20) showed that activation of NFKB, MAPK, and p300 are essential for IL-1B-induced cytosolic phospholipase A2 expression and prostaglandin E2 (PGE2) secretion. We recently demonstrated that increased PKA led to inflammation-independent activation of caspase-1 via overexpression of the protooncogene (and early osteoblast factor) Ets-1 (21) . Caspase-1 activation promotes IL-1B production, which is a potent stimulator of cyclooxygenase-2 and microsomal prostaglandin E synthase-1, the main enzymes to PGE2 elevation. High PGE2 levels in cells with defective PKA regulation increased cAMP levels and in turn activated Wnt signaling, like in other states of inappropriate PKA activity (21) .
The findings of this study have important implications for therapeutics because the two pathways (NFKB and PKA) can now be targeted interchangeably (or, maybe, simultaneously) in adrenal lesions associated with either GNAS mutation or PKA defects. Interestingly, IL-1B antagonists and caspase-1 inhibitors have been proposed as useful drugs to control the bone manifestations of patients with PKA defects or McCune-Albright syndrome (21) .
This study shows the overexpression of key genes that are part of Wnt signaling and other cancer pathways in PPNAD; ␤-catenin expression was strong in both PRKAR1A-and GNAS-mutant lesions, although in the former only within the nodules. Previous expression studies in PPNAD and AIMAH/MMAD demonstrated the overexpression of genes involved in Wnt signaling activation (11, 12, 22) . Somatic mutations of the CTNNB1 gene have been found in adrenal tumors from patients with PPNAD and CNC caused by germline PRKAR1A-inactivating mutations (23, 24) . Recently a microRNA profile analysis showed that cAMP and/or PKA via microRNA regulation affects the Wnt signaling pathway in both PP-NAD (25) and AIMAH/MMAD (26) . miR-449 was one of the highest down-regulated microRNA in PPNAD and is predicted to regulate WISP2, a gene that we had also identified as overexpressed in the adrenal glands of patients with AIMAH/MMAD and food-dependent CS (12) . The present study confirms that Wnt signaling is an important mediator of adrenal tumors related to PRKAR1A mutations, probably more so than those due to GNAS mutations.
In conclusion, this report demonstrates that not all increased cAMP/PKA signaling is the same with regard to adrenocortical tumor formation. Clearly the role of non-PKA-dependent functions of cAMP in the adrenal cortex has not been adequately investigated. These data also show that cAMP signaling inhibitors will have to be titrated for non-PKA-dependent effects if they are ever to be used as molecularly designed therapies for subclinical CS in the context of bilateral adrenal hyperplasias.
